Avalo Therapeutics (AVTX) Common Equity (2014 - 2026)

Avalo Therapeutics has reported Common Equity for 13 years, with the latest figure at $68.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 44.28% year-over-year to $68.3 million; the trailing twelve-month figure through Mar 2026 stood at $68.3 million (down 44.28% YoY), and the FY2025 full-year result was $83.0 million, down 37.57% from the prior year.
• Common Equity for Q1 2026 stood at $68.3 million, down from $83.0 million in the prior quarter.
• The five-year high for Common Equity was $133.0 million in Q4 2024, with the low at -$112.5 million in Q1 2024.
• Historically, Common Equity has averaged $29.1 million across 5 years, with a median of $7.3 million in 2023.
• The largest YoY upside for Common Equity was 1721.36% in 2024 against a maximum downside of 1695.79% in 2024.
• Avalo Therapeutics' Common Equity stood at -$10.9 million in 2022, then surged by 166.92% to $7.3 million in 2023, then surged by 1721.36% to $133.0 million in 2024, then slumped by 37.57% to $83.0 million in 2025, then slipped by 17.74% to $68.3 million in 2026.
• The last three Common Equity figures came in at $68.3 million (Q1 2026), $83.0 million (Q4 2025), and $91.5 million (Q3 2025), per Business Quant data.